Heineken has alerted British hospitality venues to a potential decline in beer and cider sales stemming from increased adoption of GLP-1 medications, including products like Ozempic and Wegovy. The world’s second-largest brewer distributed a presentation to UK pub and bar customers earlier this month outlining concerns that these weight-loss drugs may diminish customers’ desire to consume alcohol, potentially resulting in reduced pint orders and fewer multi-pint drinking occasions.
The presentation, which was disclosed to Reuters, suggested several strategies for the hospitality sector to mitigate potential revenue losses. Recommendations included promoting smaller pint sizes, expanding low- and zero-alcohol beverage offerings, and pairing drinks with small food plates. GLP-1 medications have experienced substantial growth in recent years, with approximately 10 million Americans turning to such treatments annually according to JP Morgan research, as consumers seek rapid weight loss solutions.
Heineken stated that the document was shared as part of routine engagement with UK businesses to help them understand shifting consumer behaviors. The brewer has identified specific consumption patterns among GLP-1 users, including preferences for smaller servings, lower-alcohol options, and premium products. The company noted these changes align with broader market trends reflecting younger generation consumption habits.
Responses from competing beverage firms have varied. Diageo, maker of Guinness, indicated to investors that mainstream adoption of GLP-1 drugs should pose manageable challenges, while Carlsberg told Reuters that current data does not support a connection between weight-loss drug use and beer consumption patterns. However, independent research firms including Circana, NIQ, and KAM have conducted surveys suggesting reduced alcohol consumption among GLP-1 users. British pub, bar, and restaurant beer sales reached approximately £14 billion in the year to February, with low- and no-alcohol products accounting for less than £300 million of that total.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI